gvtcx

TPOXX® Antiviral Treatment (Tecovirimat)

Department of Health and Social Care (DHSC) Published 4 Nov 2022 Contracts Finder

key details

Value£1
Statuscomplete
Category (CPV) 33651400
RegionNorthern Ireland
Deadline27 Jul 2022
Contract start28 Jul 2022
Contract end27 Jul 2023
Procedurelimited
SME suitableNo
OCIDocds-b5fd17-21875463-3a55-4fc0-842f-f3315ae7f464

Award

SupplierValueDateStatus
MERIDIAN MEDICAL TECHNOLOGIES LIMITED £1 27 Jul 2022 active

description

The monkeypox virus belongs to a family of viruses called orthopox viruses and the drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. In the current outbreak, Tecovirimat has been successfully used to treat patients with the most severe presentations of monkeypox virus infection. This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of Monkeypox in the UK.

Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate the price per dose. Publication of this information would therefore: (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors; and (iii) impact fair competition between vendors.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
4 Nov 2022 Award (award) · f2cc6672-2cdd-469b-be84-28fba800cad0-586740

more from Department of Health and Social Care (DHSC)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.